Abstract
To supplement clinical decision-making in the management of cervical cancer, various prognostic factors, including tumor immune microenvironments, were examined in patients with cervical cancer treated with definitive chemoradiotherapy. We retrospectively analyzed the expression of CD8, FoxP3, HLA-1, PD-L1, and XRCC4 in 100 cases of cervical cancer. The observed tumor immune microenvironments were also classified into three types: inflamed, excluded, and cold type. Less FoxP3+ T cells and cold-type tumor were found to be poor prognostic factors in addition to non-SCC, large pre-treatment tumor volume, and three or less cycles of concurrent chemotherapy based on multivariate analysis. Cold-type tumors had significantly worse prognoses than the other two types, whereas inflamed- and excluded-type tumors showed similar 5-year disease-specific survival (P < 0.001; 0% vs. 60.3% vs. 72.3%). Radiotherapy could overcome the inhibitory immune microenvironment that occurs in excluded type. Individualized combination therapy adapted to pre-treatment tumor immunity may be necessary to improve radiotherapy outcomes in cervical cancer.
Similar content being viewed by others
References
National Cancer Comprehensive Network 2020 NCCN guidelines: cervical cancer version 1. http://www.nccn.org/. Accessed on 1 Jan 2021.
Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, GEC ESTRO Working Group et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78:67–77. https://doi.org/10.1016/j.radonc.2005.11.014
Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R et al (2016) Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 120:428–433. https://doi.org/10.1016/j.radonc.2016.03.011
Tanderup K, Fokdal LU, Sturdza A, Haie-Meder C, Mazeron R, van Limbergen E et al (2016) Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 120:441–446. https://doi.org/10.1016/j.radonc.2016.05.014
Takada Y, Someya M, Matsumoto Y, Satoh M, Nakata K, Hori M et al (2016) Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy. Med Mol Morphol 49:210–216. https://doi.org/10.1007/s00795-016-0136-5
Tsuchiya T, Someya M, Takada Y, Hasegawa T, Kitagawa M, Fukushima Y et al (2020) Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Strahlenther Onkol 196:725–735. https://doi.org/10.1007/s00066-019-01571-1
Someya M, Tsuchiya T, Fukushima Y, Hasegawa T, Takada Y, Hori M et al (2020) Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy. Jpn J Clin Oncol 50:1290–1297. https://doi.org/10.1093/jjco/hyaa149
Camus M, Tosolini M, Mlecnik B, Pagès F, Kirilovsky A, Berger A et al (2009) Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69:2685–2693. https://doi.org/10.1158/0008-5472.CAN-08-2654
Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18:197–218. https://doi.org/10.1038/s41573-018-0007-y
Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S et al (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72:3967–3976. https://doi.org/10.1158/0008-5472.CAN-12-0851
Someya M, Hasegawa T, Tsuchiya T, Kitagawa M, Gocho T, Fukushima Y et al (2020) Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer. J Radiat Res 61:265–274. https://doi.org/10.1093/jrr/rrz099
Sakata K, Matsumoto Y, Tauchi H, Satoh M, Oouchi A, Nagakura H et al (2001) Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int J Radiat Oncol Biol Phys 49:161–167. https://doi.org/10.1016/s0360-3016(00)01352-3
Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM (2014) Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. Gynecol Oncol 135(2):208–212. https://doi.org/10.1016/j.ygyno.2014.08.018
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26(35):5802–5812. https://doi.org/10.1200/JCO.2008.16.4368
Ho CK, Kornaga EN, Klimowicz AC, Enwere EK, Dean M, Bebb GD et al (2017) Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. Gynecol Oncol 145(1):176–184. https://doi.org/10.1016/j.ygyno.2016.12.025
Shang B, Liu Y, Jiang SJ, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 14(5):15179. https://doi.org/10.1038/srep15179
Balermpas P, Martin D, Wieland U, Rave-Fränk M, Strebhardt K, Rödel C et al (2017) Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. Oncoimmunology 6:e1288331. https://doi.org/10.1080/2162402X.2017.1288331
Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T et al (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29:610–618. https://doi.org/10.1200/JCO.2010.30.5425
Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D et al (2016) Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44:698–711. https://doi.org/10.1016/j.immuni.2016.02.025
Martins PR, Machado CMT, Coxir SA, de Oliveira AJ, Moreira TB, Campos LS et al (2019) Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment. Exp Mol Pathol 111:104314. https://doi.org/10.1016/j.yexmp.2019.104314
Chen H, Xia B, Zheng T, Lou G (2020) Immunoscore system combining CD8 and PD-1/PD-L1: a novel approach that predicts the clinical outcomes for cervical cancer. Int J Biol Markers 35:65–73. https://doi.org/10.1177/1724600819888771
Hellmann MD, Friedman CF, Wolchok JD (2016) Combinatorial cancer immunotherapies. Adv Immunol 130:251–277. https://doi.org/10.1016/bs.ai.2015.12.005
Demaria S, Coleman CN, Formenti SC (2016) Radiotherapy: changing the game in immunotherapy. Trends Cancer 2:286–294. https://doi.org/10.1016/j.trecan.2016.05.002
Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515
Hegde PS, Karanikas V, Evers S (2016) The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22:1865–1874. https://doi.org/10.1158/1078-0432.CCR-15-1507
Acknowledgements
This work was supported by JSPS KAKENHI Grant Number 18K07760 and 18K07684.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Someya, M., Tsuchiya, T., Fukushima, Y. et al. Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy. Med Mol Morphol 54, 245–252 (2021). https://doi.org/10.1007/s00795-021-00290-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00795-021-00290-w